Compare Aon PLC (AON) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aon PLC vs BioNTech SE - ADR — how do they compare? Aon PLC trades at $353.5 (market cap $75.61B), while BioNTech SE - ADR trades at $92.94 (market cap $23.31B). The key difference: Aon PLC is far larger — about 3.2× BioNTech SE - ADR's market cap, and Aon PLC pays a 0.92% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| AON | BNTX | |
|---|---|---|
Market Cap | $75.61B | $23.31B |
Sector | Financials | Health |
52-Week High | $381.26 | $119.34 |
52-Week Low | $308.22 | $83.89 |
Enterprise Value | $90.22B | $6.60B |
Dividend Yield | 0.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AON trades at $351.88, down 1.43% over the past day, with a neutral technical signal and support near $350. The company reported Q2 2026 EPS of $3.81, beating estimates, and has shown consistent revenue growth, reaching $17.18B in 2025. Profitability remains strong with a net income margin of 22.27% and ROE of 44.88%, though valuation ratios like P/E of 19.65 and P/S of 4.37 are elevated relative to historical averages.
The outlook is supported by analyst consensus with a $410 price target and 47% buy ratings, but risks include high debt levels and modest organic growth. Recent news highlights institutional buying and strategic appointments, yet some analysts caution on valuation. Earnings momentum and margin expansion provide upside potential if execution continues.
BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.
The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aon PLC
Aon is a leading global provider of insurance and reinsurance brokerage and human resource solutions. Its operations are tilted toward its brokerage operations. Headquartered in London, Aon has about 50,000 employees and operations in 120 countries around the world.
Read more on AON →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
